The expected launch of potential therapies may increase the Glioblastoma Multiforme market size in the coming years, assisted by an increase in the incident population of Glioblastoma Multiforme. The market is expected to witness a significant positive shift owing to the positive outcomes of several products during the developmental stage by key players such as Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others.
“Glioblastoma Multiforme Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Glioblastoma Multiforme Market.
The Glioblastoma Multiforme Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Glioblastoma Multiforme Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Glioblastoma Multiforme and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glioblastoma Multiforme market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
Natural killer cell replacements
Epidermal growth factor receptor antagonists
Vascular endothelial growth factor receptor-2 antagonists
Platelet-derived growth factor alpha receptor antagonists
Latest Clinical, Commercial, and Regulatory Developments in the Glioblastoma Multiforme Therapeutics Market
On March 02, 2023, Genenta Science (NASDAQ: GNTA) announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).
On February 13, 2023, Jubilant Therapeutics announced that the United States Food and Drug Administration (US FDA) had granted Orphan Drug Designation (ODD) for JBI-778 for the treatment of Glioblastoma Multiforme (GBM). JBI-778 is an oral, brain penetrant, and substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor for the treatment of tumors with brain metastases and primary brain tumors, including high-grade glioma.
On January 9, 2023, Cantex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation to its drug azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.
On December 7, 2022, Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that the U.S. Food and Drug Administration (“FDA”) had granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme.
On November 17, 2022, Northwest Biotherapeutics (OTCQB: NWBO) reported that in its Phase III clinical trial, both median survival and the “long tail” of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoints under the Statistical Analysis Plan for the trial.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Glioblastoma Multiforme Therapeutic Segment @
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight
Glioblastoma Multiforme Therapeutics Landscape
There are approx. 100+ key companies developing therapies for Postoperative Pain. Currently, Oncotelic Therapeutics is leading the therapeutics market with its Glioblastoma Multiforme drug candidates in the most advanced stage of clinical development.
Leading Companies in the Glioblastoma Multiforme Therapeutics Market Include:
3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and many others
Glioblastoma Emerging and Marketed Drugs Covered in the Report Include:
Afatinib: Boehringer Ingelheim
AV-GBM-1: Aivita Biomedical
Avastin: Genentech
AZD1390: AstraZeneca
Crenolanib: AROG Pharmaceuticals
CYNK 001: Celularity
DCVax-L: Northwest Pharmaceuticals
Durvalumab (MEDI4736): MedImmune
G207: Treovir
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
LAM561 (2-OHOA): Laminar Pharmaceuticals
MDNA55: Medicenna Therapeutics
Ofranergene obadenovec (VB-111): VBL Therapeutics
ONC201: Chimerix
Onfekafuspalfa: Philogen
Paxalisib (GDC-0084): Kazia Therapeutics
PVSRIPO: Istari Oncology
Regorafenib: Bayer Healthcare
Research program: protein arginine N-methyltransferase 5 inhibitors: Jubilant Therapeutics
Selinexor (KPT-330): Karyopharm Therapeutics
Selinexor: Karyopharm Therapeutics
Tasadenoturev (DNX-2401): DNAtrix
Temodar/Temodal: Merck
Trabedersen: Oncotelic Therapeutics
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
TVB2640:Ascletis Pharma
VAL-083 (Dianhydrogalactitol): Kintara Therapeutics
VBI-1901: VBI Vaccines
YTX7739: Yumanity Therapeutics
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Glioblastoma Multiforme Current Treatment Patterns
4. Glioblastoma Multiforme – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Multiforme Late Stage Products (Phase-III)
7. Glioblastoma Multiforme Mid-Stage Products (Phase-II)
8. Glioblastoma Multiforme Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Multiforme Discontinued Products
13. Glioblastoma Multiforme Product Profiles
14. Key Companies in the Glioblastoma Multiforme Market
15. Key Products in the Glioblastoma Multiforme Therapeutics Segment
16. Dormant and Discontinued Products
17. Glioblastoma Multiforme Unmet Needs
18. Glioblastoma Multiforme Future Perspectives
19. Glioblastoma Multiforme Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
